NIH Reporter #5IK2BX005301-05

Natural killer cells in pulmonary ischemia-reperfusion injury

Award for research on natural killer cells in pulmonary ischemia-reperfusion injury to develop therapies benefiting veterans, funded by Veterans Affairs, located in San Francisco, CA.

Description

This project focuses on the role of natural killer cells in pulmonary ischemia-reperfusion injury, aiming to develop new therapeutic modalities targeting NK cells for veterans’ benefit. The award is part of a CDA-2 application, with a project start date of July 1, 2021, and end date of June 30, 2026. The funding agency is the Veterans Affairs, and the project is located in San Francisco, CA. The project involves advanced immunological research, including flow cytometry and multiplex protein quantification, to understand innate immune responses in lung injury.

View original record